

# M Hasib Sidiqi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7702637/publications.pdf>

Version: 2024-02-01

68  
papers

700  
citations

567281

15  
h-index

642732

23  
g-index

68  
all docs

68  
docs citations

68  
times ranked

940  
citing authors

#	ARTICLE	IF	CITATIONS
1	Imaging flow cytometry shows monosomy 17 in circulating plasma cells in myeloma. <i>Pathology</i> , 2022, 54, 951-953.	0.6	4
2	Checkpoint Inhibitors in Multiple Myeloma: Intriguing Potential and Unfulfilled Promises. <i>Cancers</i> , 2022, 14, 113.	3.7	5
3	Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation. <i>Blood Cancer Journal</i> , 2022, 12, 59.	6.2	3
4	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS). <i>Blood Cancer Journal</i> , 2022, 12, 62.	6.2	6
5	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 274-277.	2.4	1
6	Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2021, 56, 928-935.	2.4	5
7	Immune-mediated neuromuscular complications of graft-versus-host disease. <i>Muscle and Nerve</i> , 2021, 63, 852-860.	2.2	7
8	Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 63.	6.2	11
9	Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021. <i>Blood Cancer Journal</i> , 2021, 11, 90.	6.2	27
10	A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS8055-TPS8055.	1.6	3
11	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. <i>American Journal of Hematology</i> , 2021, 96, 1131-1136.	4.1	21
12	Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. <i>American Journal of Hematology</i> , 2021, 96, 446-454.	4.1	8
13	Long-term Outcomes of Sequential Hematopoietic Stem Cell Transplantation and Kidney Transplantation: Single-center Experience. <i>Transplantation</i> , 2021, 105, 1615-1624.	1.0	0
14	The Human Microbiota in Multiple Myeloma and Proteasome Inhibitors. <i>Acta Haematologica</i> , 2020, 143, 118-123.	1.4	14
15	Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, E8-E10.	4.1	10
16	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. <i>American Journal of Hematology</i> , 2020, 95, 4-9.	4.1	14
17	Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. <i>Bone Marrow Transplantation</i> , 2020, 55, 2132-2137.	2.4	8
18	Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1402-1405.	2.0	4

#	ARTICLE	IF	CITATIONS
19	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. <i>Blood Cancer Journal</i> , 2020, 10, 52.	6.2	8
20	Venetoclax for the treatment of translocation (11;14) AL amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 55.	6.2	36
21	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. <i>American Journal of Hematology</i> , 2020, 95, 497-502.	4.1	35
22	Depth of response prior to autologous stem cell transplantation to predict survival in light chain amyloidosis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8516-8516.	1.6	0
23	Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study. <i>Blood</i> , 2020, 136, 11-12.	1.4	2
24	Differences in Clinical Presentation and Outcomes between Metropolitan and Rural Myeloma Patients. <i>Blood</i> , 2020, 136, 44-45.	1.4	0
25	Presence of Multiple High Risk Cytogenetic Abnormalities Is Associated with Rapid Progression and Shorter Survival in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2020, 136, 23-23.	1.4	0
26	Daratumumab for the treatment of AL amyloidosis. <i>Leukemia and Lymphoma</i> , 2019, 60, 295-301.	1.3	27
27	Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. <i>Bone Marrow Transplantation</i> , 2019, 54, 442-447.	2.4	7
28	Autologous Stem Cell Transplantation in Patients with AL Amyloidosis with Impaired Renal Function. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S389-S390.	2.0	0
29	Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. <i>Blood Advances</i> , 2019, 3, 1226-1229.	5.2	7
30	Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, 1020-1026.	4.1	36
31	Improvement in Gastrointestinal Symptoms From Light Chain Amyloidosis After Adalimumab Therapy. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1380-1381.	3.0	0
32	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, 1066-1071.	4.1	14
33	Joint Pain and Proteinuria. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1512.	7.4	1
34	Autologous Stem Cell Transplant for IgM Related AL Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S388-S389.	2.0	0
35	Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1520-1525.	2.0	9
36	Impact of Allogeneic Stem Cell Transplant on Outcomes of Patients with Acute Myeloid Leukemia Based on NPM1 and FLT3 Mutational Status. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S113-S114.	2.0	1

#	ARTICLE	IF	CITATIONS
37	Two types of amyloidosis presenting in a single patient: a case series. <i>Blood Cancer Journal</i> , 2019, 9, 30.	6.2	48
38	Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. <i>Bone Marrow Transplantation</i> , 2019, 54, 1775-1779.	2.4	9
39	Impact of Chemotherapy Based Induction Using Dexamethasone, Cisplatin, Doxorubicin, Cyclophosphamide and Etoposide (DPACE) Versus Novel Agent Induction in Patients Undergoing Tandem Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S399-S400.	2.0	3
40	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, E141-E143.	4.1	17
41	Clinically significant delay in engraftment with day -1 melphalan prior to stem cell infusion in myeloma patients receiving stem cell transplant.. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e301-e302.	0.4	0
42	Venetoclax For The Treatment of Translocation AL Amyloidosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e332.	0.4	1
43	Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e108-e111.	2.0	20
44	Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1077-1081.	2.4	7
45	T-cell large granular lymphocytic leukemia and plasma cell disorders. <i>Haematologica</i> , 2019, 104, e108-e110.	3.5	9
46	Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 4560-4560.	1.4	1
47	Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucef Therapy for Lymphoma. <i>Blood</i> , 2019, 134, 4106-4106.	1.4	6
48	Outcomes of patients with light chain amyloidosis who had autologous stem cell transplantation with three or more organs involved.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8011-8011.	1.6	0
49	Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma. <i>Blood</i> , 2019, 134, 4505-4505.	1.4	0
50	Patterns of Relapse and Treatment for Relapsed/Refractory AL Amyloidosis: A Systematic Review. <i>Blood</i> , 2019, 134, 5556-5556.	1.4	0
51	Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant. <i>Blood</i> , 2019, 134, 3171-3171.	1.4	1
52	Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. <i>Haematologica</i> , 2018, 103, 1229-1234.	3.5	10
53	Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. <i>Journal of Clinical Oncology</i> , 2018, 36, 1323-1329.	1.6	100
54	Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 106.	6.2	16

#	ARTICLE	IF	CITATIONS
55	Venetoclax for the treatment of multiple myeloma. Expert Review of Hematology, 2018, 11, 915-920.	2.2	27
56	Utility and prognostic value of <sup>18</sup> F- <sup>18</sup> F- <sup>18</sup> F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2018, 93, 1518-1523.	4.1	19
57	Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. Blood Advances, 2018, 2, 769-776.	5.2	23
58	Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Advances, 2018, 2, 3149-3154.	5.2	23
59	Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2018, 24, 2360-2364.	2.0	14
60	Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. Biology of Blood and Marrow Transplantation, 2018, 24, 2157-2159.	2.0	8
61	Utility and prognostic value of 18F-FDG PET/CT scan in patients with newly diagnosed multiple myeloma.. Journal of Clinical Oncology, 2018, 36, 8023-8023.	1.6	0
62	Comparison of Different Techniques to Identify Cardiac Involvement in Immunoglobulin Light Chain Amyloidosis. Blood, 2018, 132, 3182-3182.	1.4	0
63	Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. Blood, 2018, 132, 2147-2147.	1.4	0
64	Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. Blood, 2018, 132, 5610-5610.	1.4	0
65	Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival. Blood, 2018, 132, 3436-3436.	1.4	0
66	T Cell Large Granular Lymphocytic Leukemia and Co-Existing Plasma Cell Disorders. Blood, 2018, 132, 5368-5368.	1.4	1
67	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. Blood, 2018, 132, 3160-3160.	1.4	2
68	Therapy for relapsed multiple myeloma. Panminerva Medica, 2018, 60, 174-184.	0.8	1